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Abstract
Background: Adenocarcinomas located near the gastroesophageal junction have unclear etiology and are difficult to
classify. We used DNA methylation analysis to identify subtype-specific markers and new subgroups of gastroesophageal
adenocarcinomas, and studied their association with epidemiological risk factors and clinical outcomes.
Methodology/Principal Findings: We used logistic regression models and unsupervised hierarchical cluster analysis of 74
DNA methylation markers on 45 tumor samples (44 patients) of esophageal and gastric adenocarcinomas obtained from a
population-based case-control study to uncover epigenetic markers and cluster groups of gastroesophageal
adenocarcinomas. No distinct epigenetic differences were evident between subtypes of gastric and esophageal cancers.
However, we identified two gastroesophageal adenocarcinoma subclusters based on DNA methylation profiles. Group
membership was best predicted by GATA5 DNA methylation status. We analyzed the associations between these two
epigenetic groups and exposure using logistic regression, and the associations with survival time using Cox regression in a
larger set of 317 tumor samples (278 patients). There were more males with esophageal and gastric cardia cancers in Cluster
Group 1 characterized by higher GATA5 DNA methylation values (all p,0.05). This group also showed associations of
borderline statistical significance with having ever smoked (p-value=0.07), high body mass index (p-value=0.06), and
symptoms of gastroesophageal reflux (p-value=0.07). Subjects in cluster Group 1 showed better survival than those in
Group 2 after adjusting for tumor differentiation grade, but this was not found to be independent of tumor stage.
Conclusions/Significance: DNA methylation profiling can be used in population-based studies to identify epigenetic
subclasses of gastroesophageal adenocarcinomas and class-specific DNA methylation markers that can be linked to
epidemiological data and clinical outcome. Two new epigenetic subgroups of gastroesophageal adenocarcinomas were
identified that differ to some extent in their survival rates, risk factors of exposure, and GATA5 DNA methylation.
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Promoter CpG island hypermethylation is a common occur-
rence in human cancers, and is generally associated with
transcriptional silencing of the associated gene [1,2]. Although
much of the focus has been on tumor-suppressor genes silenced by
promoter hypermethylation, many CpG island hypermethylation
events occur either outside of promoters, or at genes without a
known role in cancer, or even at genes normally not expressed in
that particular cell lineage. Thus, many CpG island hypermethy-
lation events are likely to reflect passenger events, rather than
drivers of the oncogenic process. We and others have shown that
targets for transcription repression by the Polycomb group (PcG)
proteins in human embryonic stem cells are particularly
predisposed to CpG island hypermethylation in cancer [3,4,5].
Irrespective of their role in the oncogenic process, all cancer-
specific DNA methylation changes constitute potential biomarkers
that might be exploited as clinical tools for diagnosis or early
detection of cancer, appraisal of disease progression or response to
therapy, or risk assessment in surveillance programs [6].
Esophageal adenocarcinoma (EAC) is a very aggressive disease
that metastasizes early and has a poor prognosis with 5-year
survival rates less than 40% [7]. For reasons that are not well
understood, the incidence of this type of cancer has increased in
the past three decades in the Western industrialized countries
especially among white males [8,9]. Gastroesophageal reflux
disease (GERD) is a major risk factor for this type of cancer [10].
EAC arises from the epithelial lining of the distal esophagus,
particularly when this mucosa has undergone metaplastic change,
characteristic of Barrett’s esophagus. The epithelium of the
gastroesophageal junction shares histological characteristics with
distal esophageal mucosa, and is quite distinct from epithelium
lining the gastric cardia (proximal stomach) or distal regions of the
stomach. However, tumors arising in the gastric cardia share more
clinical, epidemiological and molecular features with EAC than
with tumors arising in the distal part of the stomach. Moreover,
while the incidence of distal gastric adenocarcinoma (DGA) has
decreased dramatically during the past five decades, the incidence
of gastric cardia adenocarcinoma (GCA) has increased slightly
especially among men in Western countries and then remained
relatively stable since 1990 [11,12]. This suggests that the reflux-
associated EAC and adenocarcinoma of the gastric cardia and
gastroesophageal junction could be considered to be etiologically
related and possibly reflective of a similar disease process [13,14].
However, many clinicians view these diseases as distinct entities
that would require better means than pathological evaluation for
their classification [15].
We have previously shown that DNA methylation profiles differ
between normal squamous esophageal mucosa and the very early
precursor lesions of EAC, Barrett’s intestinal metaplasia, and
dysplasia [16,17]. We have also shown that hypermethylation of
the APC gene promoter in the plasma of patients with EAC is
associated with reduced patient survival [18]. Since then, more
groups have reported other DNA methylation abnormalities in the
gastroesophageal cancers [19,20,21]. However, there are only few
reports in which large numbers of tumor samples and markers
have been used in epigenetic profiling experiments or to identify
the associations of epigenetic alterations with clinical pathological
and lifestyle risk factor data.
In this study we performed a large-scale DNA methylation
analysis on a subset of 318 tumor samples (279 patients) of
esophageal and gastric adenocarcinomas obtained from a multi-
ethnic population-base case-control study using a total of 79 DNA
methylation markers. The main goal of the study was to identify
markers that distinguish the different types of cancer in the
esophageal-gastric continuum, as well to identify novel subgroups
of gastroesophageal cancers based on their DNA methylation
profiles and to assess their association with known epidemiological
risk factors and clinical outcomes. This study was also intended to
explore the possibility of using DNA methylation analysis to
conduct future population-based studies that typically have limited
amounts of paraffin-embedded tissues specimens, but have the
advantage of availability of extensive clinical/pathological and
lifestyle risk factor data.
Materials and Methods
Ethics Statement
This study was conducted in accordance with the Helsinki
human subjects doctrine and was approved by the Institutional
Review Board of the Keck School of Medicine of the University of
Southern California. Signed informed consent was obtained from
all study participants for the collection of the samples and their
subsequent analysis.
Specimen collection and selection for methylation and
statistical analyses
Patients included in this study were cases from a population-
based case-control study of esophageal and gastric adenocarcino-
ma we conducted in Los Angeles County [22]. In brief,
histologically confirmed esophageal or gastric adenocarcionomas
were identified from the NCI Surveillance, Epidemiology and
End-Results Program (SEER) population-based cancer registry
covering Los Angeles County, the USC Cancer Surveillance
Program (CSP). A total of 942 patients (222 esophageal
adenocarcinomas, 277 gastric cardia adenocarcinomas, and 443
distal gastric adenocarcinomas) were interviewed and 879 signed a
medical release giving us permission to obtain their tumor samples
from the hospital of diagnosis. Tumor blocks were obtained on
542 patients but the amount of tumor tissue was too small or
degraded for 162 patients and thus DNA material was available on
380 patients (97 esophageal adenocarcinomas, 105 gastric cardia
adenocarcinomas, 178 distal gastric adenocarcinomas). We
obtained 523 formalin-fixed paraffin-embedded slides from 380
patients but had to further exclude another 83 slides after
prescreening the samples for DNA quantity. We selected only the
332 tumor samples (292 patients) from the remaining 440 samples
to perform the DNA methylation analysis. We further excluded 14
samples (13 patients): one sample was from a patient that had
previous cancer, eight samples did not have gastric/esophageal
tissues, and five samples were omitted because the reported daily
caloric intake of these patients was either too low (#500 calories
per day) or too high (.7,000 calories per day). The remaining 318
tumor samples (279 patients) were used in the DNA methylation
analysis. Forty five of these samples (44 patients) were used in the
cluster analysis while the evaluation of the association between the
epidemiological and DNA methylation data was performed on a
subset of 317 of these tumor samples (278 patients). One tumor
sample from a recurrent cancer was included in the cluster analysis
but not in the association analysis for epidemiological risk factors.
The criteria used for subject selection and sample usage are
presented in the Table S5.
DNA preparation
DNA was extracted from tissue samples contained in paraffin
blocks. One five- micron section lightly stained with hematoxylin
and eosin was prepared from each paraffin block and examined by
our study pathologist (G.H. Kang) in order to mark the location of
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on the slide. Tissues from these various regions were carefully
microdissected from 1–4 serial stained sections and placed into
separate microcentrifuge tubes. DNA was extracted by adding
20 ml of lysis buffer (100 mM Tris, 10 mM EDTA Proteinase K
2 mg/ml, tRNA 0.05 mg/ml) to each sample. If the amount of
tissue dissected was in excess, the volume of lysis buffer was
increased proportionally. Tissues were digested overnight at 50uC
in an incubator with continuous shaking. We added 5 ml of water
to each tissue lysate and stored the samples at 220uC until bisulfite
conversion.
Bisulfite conversion and DNA methylation analysis
Eighteen microliters of the tissue lysate solution, containing the
extracted DNA, were treated with sodium bisulfite as previously
described [23]. DNA methylation measurements are reported as
PMR (Percent of Methylated Reference) values, as previously
described [23]. In order to estimate the number of reactions that
can be analyzed for each sample, we tested a small aliquot of the
recovered bisulfite-converted DNA by real time PCR using an
ALU-based bisulfite specific, methylation-independent control
reaction (HB-313 reaction in Table S1). A total of 79 DNA
methylation markers were selected for study and analyzed by
MethyLight as described previously [24,25]. Some of these DNA
methylation markers have been described in the literature, while
others were developed in our own laboratory for known tumor
suppressor gene promoters. Several of these markers have
previously shown variability in their DNA methylation levels
among tumors of a specific type. We exploited this characteristic in
order to investigate the potential associations between specific
epigenetic changes in tumors and epidemiological risk factors of
exposure. A complete list of the markers used is provided in the
Tables S1 and S2. The sample and marker utilization in the DNA
methylation analysis is depicted in the Figure S1.
Epidemiological and Clinical Data
Demographic characteristics included age at diagnosis (contin-
uous), race (white/non-white), and gender, obtained routinely
from the USC CSP at the time of cancer reporting. A history of
personal exposures one year prior to diagnosis were obtained from
an in-person structured interview [22] including smoking history,
dietary intake, height, body weight at age 20, age 40, and at
diagnosis, and history of reflux diseases/symptoms. Smoking
history was evaluated in a number of different ways. First, we
considered smoking as a categorical variable, classifying individ-
uals as never, former or current smokers. We also evaluated the
average number of cigarettes smoked per day, the age when
subjects started and stopped smoking, the total years of smoking,
and the number of pack-years of cigarettes smoked.
From dietary questionnaires, information on total calories (in
kcal), folate acid (in mg/1000 kcal), total fat (in gram/1000 kcal),
and dietary fiber (in gram/1000 kcal) was obtained. Information
on the following GERD symptoms three or more years prior to
diagnosis was obtained: sour stomach, gas pain, heartburn, and
swallow symptoms (none, 1, 2, 3 or 4).
Information on tumor characteristics was obtained from the
USC CSP. For this analysis, we considered the anatomic site
(EAC, GCA and DGA), clinical stage (in situ or localized; regional,
direct extension, or lymph nodes only; regional, direct extension,
and lymph nodes; distant metastases; unstageable), tumor size (in
millimeter), and tumor differentiation (well differentiated; moder-
ately differentiated; poorly differentiated; undifferentiated; un-
known differentiation). Time of follow-up from diagnosis (in years)
was calculated from vital status information obtained from the
USC CSP.
Cluster Analysis
We performed a two-dimensional unsupervised hierarchical
cluster analysis of the DNA methylation profiles. Pearson
correlations are calculated as pair-wise distance metric, and
clusters are combined using the Ward method, which merges
clusters that give the minimum increase in error sum of square
within cluster [26]. Measures of DNA methylation give a non-
negative continuous value reporting the percent of methylated
reference (PMR). PMR values are transformed on the natural log
scale (ln(PMR+1)) and standardized across gene markers before
use in the above cluster analysis.
Statistical analysis for epidemiological risk factors
assessment and clinical outcome
We performed logistic regression using Generalized Estimating
Equations (GEE) and robust variance estimates to evaluate the
associations between the DNA methylation group variable and all
other variables of interest. To evaluate the associations between
the number of methylated genes (0–9) and the variables of interest
we used a linear link function. A PMR of 10 was used as a cut
point for each DNA methylation marker. These approaches
allowed us to analyze all tumor samples, accounting for the
correlation in outcome among tissue samples obtained from a
single patient. P-values were reported both with and without
adjusting for covariates. In the analyses with adjustment, we
controlled for sex and/or tumor site. Adjusted odds ratios and
95% confidence intervals (CI) were reported.
Patient survival was analyzed using a Cox regression model,
with DNA methylation group as a predictor variable. For subjects
with more than one tissue sample, the average group value was
used as a summary for DNA methylation group membership.
Tumor stage, differentiation, site, sex and the number of
methylated genes were tested as potential important predictors.
For subjects with more than one tissue sample, the average
number of methylated genes was used as a substitute for the
number of methylated genes. Hazard ratios (HR) with 95% CIs
and p-values were calculated and reported for the above
continuous and categorical variables. Trend effects for the ordinal
categorical variables in relation to survival were also evaluated
using ordinal coding for the variables in the Cox regression model.
Furthermore, we analyzed the relationship between the summary
group variable and survival after adjusting for either tumor stage
or tumor differentiation. The association of the summary DNA
methylation group and the subjects’ survival times were assessed
using the log rank test for those in either Group 1 or Group 2. All
p-values reported are two-sided and were evaluated at the 0.05
level. We accounted for multiple testing using the Benjamini and
Hochberg approach [27].
Results
DNA methylation profiles of gastroesophageal tumors
We generated DNA methylation profiles of gastroesophageal
tumor tissue samples using a panel of 79 markers (Table S1 and
S2) by MethyLight analysis. The samples included three different
types of gastroesophageal tumors, EAC, GCA, and DGA. Some of
the 79 selected markers have been previously tested on a limited
number of EAC tissues [17]. The remaining markers have been
reported to be either methylated in other types of cancers, or were
recognized for their potential involvement in cancer development
(Table S1). Due to the variability in the amounts of DNA obtained
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four groups according to their DNA content (see Figure S1). The
group of samples having the highest amount of DNA was analyzed
with all 79 markers; the group of samples with the lowest DNA
quantity was analyzed with only 9 markers, while those with
intermediate DNA quantities were analyzed with either 19 or 39
markers. In total, 318 tissue samples (279 patients) were evaluated
for 9 markers, of these, 178 samples (156 patients) were evaluated
for an additional 10 markers (19 markers total), 107 (96 patients)
were evaluated for an additional 20 markers (39 markers total),
and 45 (44 patients) were evaluated for an additional 40 markers
(79 markers total) (See Table S5). The choice of DNA methylation
markers used for each sample set was based on their degree of
variability across various tissue types observed in previous studies
[16,17,25,28,29], and their biological significance.
Identification of subtype-specific DNA methylation
markers and novel DNA methylation subclasses for
gastric and esophageal cancers
Out of the 79 DNA methylation markers tested on the 45 tumor
samples with the highest amount of DNA available, five markers
showed no detectable DNA methylation across all tumors and
were excluded from subsequent analysis. We used the remaining
74 informative markers to identify subtype-specific markers and
perform cluster analysis for subclass discovery. Using linear
regression we found four DNA methylation markers, MT2,
SFRP2, TFAP2A, and TWIST1, that showed individual association
with tumor subtype at p,0.05 significance level, however, after
adjusting for multiple comparisons, none of these associations
remained statistically significant.
In order to summarize the variation in the DNA methylation
profiles and to identify new DNA methylation-based tumor
subgroups we next performed a two-dimensional unsupervised
hierarchical clustering analysis of the same 45 samples and 74
DNA methylation markers. The cluster analysis identified two
major sub-groups of gastroesophageal tumors with distinct DNA
methylation profiles (Figure 1). There were 27 tumors (27 patients)
in the Group 1 and 18 tumors (17 patients) in Group 2. Among the
74 markers, the DNA methylation of the GATA5 marker showed
the highest statistical difference between the two groups
(p=0.005). The ability of GATA5 marker to distinguish between
the two groups was assessed by a Receiver Operating Character-
istic (ROC) curve analysis that resulted in an area under the curve
(AUC) value of 0.97. To investigate the dependence of these two
clusters on GATA5, we repeated the clustering excluding GATA5
from the analysis obtaining a classification accuracy of 93% (42/
45) (not shown). This indicates that although GATA5 is a good
representative marker for this classification, it is not solely, or even
primarily, responsible for driving the classification.
In order to classify all tumor tissues into the two DNA
methylation subgroups, we used logistic regression and the nine
markers measured on all 318 tumor tissues to build a classifier for
the cluster group outcome. In a model that included GATA5, none
of the remaining 8 markers added significantly to the prediction of
the subgroup (all p.0.05). Using a PMR cut point of 81.4, GATA5
could predict whether a tumor belonged to Group 1 with 92.6%
sensitivity and 94.4% specificity (Figure 1).
Association between GATA5-based DNA methylation
clusters, clinical characteristics, and epidemiological risk
factors
We next correlated the nine DNA methylation markers
measured on the full set of 317 tumor samples (278 patients) with
the clinical and environmental risk variables. Three of the
markers, GATA5, ITGA4, and RUNX3 were significantly associated
with various exposures, such as smoking status (data not shown).
However, the associations were no longer significant after
adjusting for multiple comparisons. We also did not find any
significant associations between the number of methylated genes in
the analyzed tumor samples and any of the clinical characteristics
or epidemiological risk factors. As an alternative, we then used the
two newly identified DNA methylation subgroups to study their
association with environmental exposures and clinical outcome.
We defined the DNA methylation subgroups using the GATA5 cut
point of 81.4 identified using the 45 tumor samples in the cluster
analysis.
Applying this classification criterion to the full set of 317 tumor
samples (278 patients, the final classification assigned 186 tumor
samples (160 patients) to Group 1 and 131 samples (120 patients)
to Group 2. Table 1 shows the characteristics of the two DNA
methylation groups.
There was a difference in the proportion of males between the
groups that remained statistically significant even after adjusting
for tumor type (p=0.03). The association with race did not
Figure 1. Unsupervised cluster analysis of DNA methylation
markers and gastroesophageal adenocarcinimas. Heat map of
the standardized (log-transformed percent of methylated reference
(PMR) values) DNA methylation values for 74 genes (columns) in 45
gastroesophageal tumor samples (rows) from 44 patients. The
clustering was performed using the Ward method. Similar methylation
patterns were clustered closely, and two major sample groups were
formed based on the DNA methylation profiles of these 74 genes. Based
on the Ward method (W, left color bar), the lower 27 samples/27
patients (dark green) were assigned to Group 1, and the upper 18
samples/17 patients (light green) were assigned to Group 2. Based on
GATA5 DNA methylation criterion (G, right color bar), 26 samples/26
patients (dark green) belonged to Group 1, and 19 samples/18 patients
(light green) belonged to Group 2. The arrow at the bottom of the
diagram shows the GATA5 DNA methylation column. Red color in the
diagram represents high-standardized DNA methylation values. Yellow
color in the diagram represents low-standardized DNA methylation
values.
doi:10.1371/journal.pone.0025985.g001
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into consideration, and the mean age at the time of diagnosis
did not differ by group. BMI at ages 20 and 40 (Table S3) was
not associated with the two groups but BMI at the time of
diagnosis was borderline significantly associated with DNA
methylation group (p=0.06) after adjusting for tumor type and
sex (Table 1).
Smoking status was borderline statistically significantly associ-
ated with the DNA methylation group (p=0.07) after sex and
tumor type were taken in consideration (Table 1). The proportion
of patients who had ever smoked was higher in Group 1 than in
Group 2; this was mainly due to an excess of former smokers
(51.1% in Group 1 vs. 29.0% in Group 2 were former smokers).
However, there were no significant differences in the average
Table 1. Characteristics of DNA Methylation Groups.
{
Group 1 Group 2
186 tissues/160
patients
131 tissues/120
patients p-value1
1
Adjusted
p-value2*
Mean GATA5 DNA methylation (SD) 286.9 (235.6) 22.0 (23.1)
Subject Characteristics (% of tissues)
Sex Male 161/137 (86.6%) 93/86 (71.0%) 0.003 0.03**
Race White 141/116 (75.8%) 83/74 (63.4%) 0.03 0.90
Mean age at diagnosis (in years) (SD) 61.3 (8.6) 60.2 (10.9) 0.35 0.79
Mean BMI at diagnosis (in kg/m
2) (SD) 27.7 (5.2) 25.8 (6.0) 0.045 0.06
Missing (count) 7/7 15/13
Smoking status 0.003 0.07
Never 41/37 (22.0%) 51/45 (38.9%)
Ever 145/123 (78.0%) 80/75 (61.1%)
Former smokers 95/81 (51.1%) 38/36 (29.0%)
Current smokers 50/42 (26.9%) 42/39 (32.1%)
Mean number of cigarettes per day (SD) 43.3 (33.5) 53.3 (38.8) 0.03 0.14
Total fat (in gram/1000 kcal) 43.1 (7.7) 40.4 (9.1) 0.01 0.26
Presence of symptoms: sour stomach, gas pain, heartburn, and swallow symptoms 0.01 0.07
None 85/74 (48.0%) 77/70 (62.1%)
One 30/24 (17.0%) 21/19 (16.9%)
Two 44/37 (24.9%) 13/13 (10.5%)
Three or four 18/17 (10.2%) 13/12 (10.5%)
Missing (count) 9/8 7/6
Tumor Characteristics (% of tissues)
Tumor site/subtype 0.0003 0.003***
Esophageal Adenocarcinoma 73/60 (39.3%) 29/29 (22.1%)
Gastric Cardia Adenocarcinoma 74/61 (39.8%) 47/38 (35.9%)
Distal Gastric Adenocarcinoma 39/39 (21.0%) 55/53 (42.0%)
Tumor stage 0.18 0.28
1) In situ or localized 38/35 (20.4%) 22/20 (16.8%)
2) Regional, direct extension or lymph nodes only 32/24 (17.2%) 20/18 (15.3%)
3) Regional, direct extension & lymph nodes 62/53 (33.3%) 34/30 (26.0%)
4) Distant metastases or unstageable 54/48 (29.0%) 55/52 (42.0%)
Mean tumor size (mm) (SD) 50.2 (22.5) 52.8 (28.5) 0.51 0.66
Size unknown (count) 58/53 41/41
Tumor differentiation 0.20 0.23
Well or Moderately differentiated 50/39 (26.9%) 34/32 (25.9%)
Poorly differentiated 123/108 (66.1%) 79/70 (60.3%)
Undifferentiated 8/8 (4.3%) 7/7 (5.3%)
Differentiation unknown 5/5 (2.7%) 11/11 (8.4%)
{Except for those specified, the information in this table means Count of Tissue Samples/Count of Subjects (% tissues) or Mean (SD).
1p-value1 was computed using GEE and no adjustment variables.
*p-value2 was calculated using GEE after adjusting for tumor site and sex.
**p-value was calculated for the sex variable using GEE after adjusting for tumor site.
***p-value was calculated for the tumor site variable using GEE after adjusting for sex.
doi:10.1371/journal.pone.0025985.t001
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other smoking parameters (Table S3) after adjusting for sex and
tumor type. None of the four dietary variables investigated in this
analysis differed significantly between the groups (Table S3).
Intake of total fat was significantly lower in Group 2 compared to
Group 1 (p=0.01), but this finding was substantially weakened
after sex and tumor type adjustment (p=0.26) (Table 1). In
addition, the history of digestive gastrointestinal symptoms (sour
stomach, gas pain, heartburn and swallow symptoms) prior to the
diagnosis of cancer was borderline significantly associated with the
groups after adjusting for sex and tumor type (Table 1).
Table 1 (bottom half) summarizes the tumor characteristics of the
two DNA methylation groups. Tumor site/subtype differed
significantly between Group 1 and Group 2 after adjustment for
sex (p=0.003). Esophageal and gastric cardia adenocarcinomas
accounted for 39.3% and 39.8%, respectively, of subtypes in Group
1, while 42.0% of samples in Group 2 were distal gastric
adenocarcinomas. There were no significant differences in tumor
stage, size, or degree of differentiation between groups (all p.0.05).
In the analysis of all tissue samples, only two subjects had tissues
discordant for GATA5 subgroup. A subject-level analysis, classify-
ing subjects into groups based on their average GATA5
methylation value, showed results similar to those in Table 1
(results not shown). The associations between GATA5 subgroup
and BMI, and GATA5 subgroup and smoking remained
statistically significant even after adjusting for sex and tumor site
(p=0.03 and 0.04 respectively).
The significant associations between the DNA methylation
groups and several variables of interest were reflected in the
calculated odds ratios (Table S4). More subjects in Group 1 had
esophageal or gastric cardia adenocarcinoma than those in Group
2. Males were twice as likely to belong to Group1 than females
(95% CI=1.11–4.03) after controlling for the effect of tumor site,
although there were no significant differences in whites versus non-
whites. There were twice as many ever smokers in Group 1 than in
Group 2 (see Table S4).
Association between GATA5-based DNA methylation
clusters and survival characteristics
The median survival time for the patients in Group 1 was longer
than those in Group 2 (Table 2). The Kaplan-Meier Survival
curves indicated a better overall survival for patients in Group
1(log-rank p=0.04, Figure 2). However, the stage and the degree
of differentiation of the tumors were also independently associated
with the survival time (log-rank p,0.0001 and p=0.01 respec-
tively). The mortality risk of the patients with more advanced stage
disease was higher than those with in situ or localized tumors, with
as much as 6.5-fold higher mortality risk for those with distant
metastases or unstageable disease. Compared to patients with well-
or moderately-differentiated tumors, patients with undifferentiated
tumors had higher rates of death (HR=1.88, 95% CI=1.05–
3.37). The higher mortality risk assessment of Group 2 patients did
not change after adjustment for tumor differentiation (95%
CI=1.14–1.93, p=0.004). However, after adjusting for tumor
stage, the association between DNA methylation subgroup and
mortality risk disappeared (stage adjusted HR=1.2, 95%
CI=0.88–1.5, p=0.30). Except for the above three variables,
we did not find any other statistically significant predictors for
patient survival (all p.0.05) (Table 2).
Discussion
Previous DNA methylation studies of esophageal and gastric
cancers indicated that cancer-associated DNA methylation
changes could be used as molecular tools to explore and understand
the clinical and epidemiological features associated with these
diseases. Our present study allowed us to validate the feasibility of
conducting population-based studies using DNA methylation
analysis on single slides of formalin-fixed paraffin-embedded tissues
specimens.Thesestudiesaretechnicallychallenging duetothe large
number of samples and markers involved in the analyses, and to
issues related to sample integrity associated with the preservation
process of archival specimens. The MethyLight technology
employed in this study is one of the few available high-throughput
DNA methylation assays compatible with automation that can also
be applied to single slides of paraffin-embedded tissues. Despite our
efforts to include a large number of cases in the DNA methylation
analysis, our emphasis in obtaining high-quality data, made it
necessary to eliminate many samples, due to the low quality and
quantity of the DNA extracted from the paraffin-embedded tissues.
However, the final sample set included 278 individuals with
information on survival time, 239 of whom had died, providing
sufficient numbers of individuals to explore association between
DNA methylation and clinical outcome.
We were not able to identify DNA methylation profiles and
markers capable of distinguishing between the different subtypes of
gastric and esophageal cancers using our collection of 79 reactions.
Our finding is supportive of results of a recent study that showed
modest differences in DNA methylation between normal gastric
cardiac mucosa and esophageal squamous mucosa, despite
considerable differences in histology and expression profiles
between these tissues [21]. These findings underscore the need
of using genome-wide approaches with larger numbers of DNA
methylation markers and larger sets of normal and pathological
samples in order to achieve this goal.
We successfully identified two new subgroups of tumors with
distinct DNA methylation profiles among the esophageal and
gastric cardia adenocarcinomas that could be best predicted by
DNA methylation of the GATA5 marker alone. Membership in the
two newly identified epigenetic groups was significantly correlated
with sex and tumor subtype. Epigenetic Group 1, characterized by
higher levels of GATA5 DNA methylation, consisted mainly of
men with esophageal or gastric cardia adenocarcinomas. If gender
and tumor type are not taking in consideration, the patients in
Group 1 were more likely to be smokers or former smokers, had
higher BMI values, and experienced symptoms of gastro-
esophageal reflux compared to patients in Group 2. Despite the
decrease in significance after adjusting for gender and tumor
subtype, our findings still suggest a possible combined effect of
tobacco, gastrointestinal fluid, dietary micronutrients alterations or
products of fat metabolism to induce specific hypermethylation
changes associated with the distinct phenotype of EAC and GCA
tumors in Group 1. Moreover, the association between the GATA5
subgroup and BMI and smoking remained statistically significant
even after adjusting for sex and tumor subtype when subjects
rather than samples were used in the analysis. Group membership
appeared to be also a significant predictor for overall survival, but
not after controlling for tumor stage. It is possible that tumor stage
(and to a lesser extent tumor differentiation) accounted for most of
the differences in the patient survival between groups. However,
since these two variables did not differ significantly between
groups, the association between the methylation groups and
overall survival deserves further investigation in future studies.
These two new epigenetic groups would require further confir-
mation in independent populations.
Abnormal DNA methylation of the GATA5 gene promoter with
subsequent loss of function has been previously reported in several
cancers including esophageal, [30], gastric [31], colorectal,
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spectrum of cancers in which GATA5 DNA methylation has been
documented suggests that GATA5 DNA methylation is not cancer
type specific. In our study, GATA5 DNA methylation, was also not
significantly associated with any of the three gastroesophageal
tumor subtypes. This conclusion is also in agreement with the
observations that GATA5 DNA methylation is a common marker
for both types of esophageal cancers, EAC and esophageal
squamous cell carcinoma (ESCC) [30], as well as for three
different types of lung cancers that each have distinct cells of origin
[33]. These results suggest that high GATA5 DNA methylation
levels may be associated with defects in a specific molecular
pathway that is common for cells of different embryological origin.
It has also been suggested that DNA methylation-mediated loss of
GATA5 function may impede the normal process of differentia-
tion and thus contribute to tumorigenesis [31]. However, our
finding showing a lack of association between the GATA5
methylation or GATA5 methylation-based groups and the degree
of tumor differentiation does not support this hypothesis.
The possible mechanisms linking DNA methylation changes to
any of the three exposure risk factors detected in this study are not
yet known. Several studies have shown a positive association
between smoking and methylation of specific genes in various
cancers. Smoking induced DNA damage was suggested to cause
abnormal promoter DNA hypermethylation in lung cancer [35].
Interestingly, smoking status was not associated with GATA5 DNA
methylation in a study of lung cancers [33]. However, in the same
study it was reported that the length of time a person smoked was
significantly associated with GATA5 DNA methylation, while the
former smokers showed a trend towards statistical significance of
more frequent GATA5 DNA methylation [33]. Moreover, GATA5
promoter DNA methylation was shown to be associated with high
levels of DNA damage caused by radiation exposure [36]. Our
results, together with the observations in lung cancers suggest that
high levels of GATA5 DNA methylation could be linked to
molecular pathways involving DNA damage and repair due to
exposure to DNA damaging agents such as the carcinogens in
tobacco. Also, quitting smoking may not reverse the process.
Table 2. Association of patient and tumor characteristics with survival time.
Variable
Number of patients
(N=278)
Number of death
(N=239) Hazard Ratio (95% CI)* p-value*
DNA methylation Group 0.04
Group 1 160** 135** 1.00
Group 2 118 104 1.31 (1.01–1.69)
Sex 0.07
Male 221 198 1.00
Female 57 41 0.73 (0.52–1.02)
BMI at diagnosis 0.99 (0.96–1.01) 0.29
Smoking status 0.90
Never 82 70 1.00
Former 116 102 0.97 (0.72–1.32)
Current 80 67 1.05 (0.75–1.47)
Tumor site 0.42
Esophageal Cancer 88 79 1.00
Gastric Cardia 98 87 1.09 (0.80–1.47)
Distal Gastric 92 73 0.88 (0.64–1.21)
Tumor size 1.01 (1.00–1.01) 0.06
Tumor stage ,0.0001
1) In situ or localized 55 36 1.00
2) Regional, direct extension or lymph nodes only 42 31 1.39 (0.86–2.26)
3) Regional, direct extension & lymph nodes 82 73 2.48 (1.65–3.73)
4) Distant metastases or unstageable 99 99 6.54 (4.35–9.86)
Trend effect on tumor stage 1.93 (1.68–2.21) ,0.0001
Tumor differentiation 0.04
Well- or Moderately-differentiated 71 59 1.00
Poorly-differentiated 176 154 1.21 (0.90–1.64)
Undifferentiated 15 14 1.88 (1.05–3.37)
Differentiation not known
{ 16 12 0.67 (0.36–1.25)
Trend effect on tumor differentiation 1.29 (1.00–1.66) 0.05
*Hazard ratios, 95% CIs, and p-values were calculated using Cox regression.
**Two subjects with multiple tissue samples that have different DNA methylation group values were included in Group 1 here. They both died before the end of the
study.
{This category was not included in the trend test.
doi:10.1371/journal.pone.0025985.t002
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may also explain the higher levels of GATA5 DNA methylation in
former smokers compared to current smokers. Presently, the
mechanism targeting GATA5 for methylation in the context of
DNA damage is unclear. It is interesting to note that GATA5 is one
of the genes targeted by the Polycomb group for transcription
repression in human embryonic stem cells [3], of which a large
majority of genes become abnormally hypermethylated in cancers.
The relationship between DNA damage and hypermethylation of
genes targeted by Polycomb repression in embryonic stem cells
remains to be determined.
A positive association between high BMI and methylation levels
of a Line region has been recently reported in head and neck
squamous cell carcinoma [37]. The effect of a high BMI on DNA
methylation levels may be due to inadequate intake, absorption or
metabolism of dietary micronutrients such as folate known to be
important for normal DNA methylation [38]. Overweight people
have lower levels of multiple micronutrients including folate [39].
However, our study did not reveal any significant differences
between groups with respect to the dietary variable analyzed
including the folic acid levels in the diet. It is also possible that
byproducts of the fat metabolism might have a direct effect on
epigenetic state. The effects of a high BMI on DNA methylation
may be however indirect, mediated by the gastroesophageal reflux
that is more common in obese people due to decrease in lower
esophageal sphincter function combined with increased intra-
abdominal pressure [40]. GERD is thought to mediate the
transformation of squamous esophageal epithelium into Barrett’s
intestinal metaplasia [41] and of gastric cardia mucosa into cardia
intestinal metaplasia (CIM) [42]. Abnormal DNA methylation
changes specific for EAC and GCA are present in these early
lesions [16]. However, the direct effect of the various components
of the refluxed juice or the accompanying inflammatory process on
DNA methylation has not yet been thoroughly investigated.
The significance of these new epigenetic subclasses of
gastroesophageal cancers and their independent or combined
possible association to different life style factors will need to be
evaluated in future studies using larger number of samples and a
more comprehensive marker selection. Also, other yet unmeasured
risk factors such as Helicobacter pylori infection that may act as
confounders, should be taken in consideration in these studies.
The identification of markers specific for these epigenetic
subclasses of cancers may also help shed light on the molecular
mechanisms leading to their development, and become useful tools
for clinicians for early detection, prognosis, and prevention of
these types of cancers.
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